Fig. 5

Blocking M2 polarization of TAMs and Macrophage depletion inhibited the SPON2-induced tumors growth and invasion. a Gross images of MC38/Vector + PBS, MC38/SPON2 + PBS and MC38/SPON2 + IL10 subcutaneous tumor. b Growth curve in the different treatment groups. Two-way ANOVA test, *p < 0.05, **p < 0.01. c Anti-IL10 neutralizing antibody treatment time diagram and fold change of tumor volume in each case (final volume / initiate volume). d Hematoxylin and eosin (H&E) staining shows the histology of subcutaneous tumor tissues. IHC shows tumor cells with SPON2 expression. The arrows indicated the tumor invasion. Scale bar, 50 μm. e Flow cytometric quantification showing percentages M2-TAMs of all CD45 + cells in subcutaneous tumors, **p < 0.01. f Gross images of MC38/Vector and MC38/SPON2 subcutaneous tumors in C57BL/6 mice treated with BLZ945 or isotope control (DMSO). g Tumor growth curve in the different treatment groups. Two-way ANOVA test, ****p < 0.0001. h BLZ945 treatment time diagram and fold change of tumor volume in each case (final volume / initiate volume). i Tumor weights of mice in the different treatment groups at the end point. *p < 0.05. j Hematoxylin and eosin (H&E) staining shows the histology of subcutaneous tumor tissues. IHC shows tumor cells with SPON2 expression. The arrows indicated the tumor invasion. Scale bars, 50 μm. k Flow cytometric quantification showing the effect of SPON2 on the infiltration of M2-TAMs upon BLZ945 treatment. **p < 0.01